| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/12/2001 | EP0682514B1 Use of topical anesthetics for the manufacture of a medicament for the treatment of bronchial asthma |
| 09/12/2001 | EP0630240B1 Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (gaba) agonists |
| 09/12/2001 | CN1312725A Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
| 09/12/2001 | CN1312720A Method and system for production and collection of lavage induced stool (LIS) for chemical and biologic tests of cells |
| 09/12/2001 | CN1312718A Selective estrogen receptor modulator in combination with sex steriod precursors and the like |
| 09/12/2001 | CN1312715A Antihypersensitive combination of valsartan and calcium channel blocker |
| 09/12/2001 | CN1312714A Pharmaceutical composition containing lipase inhibitors and chitosan |
| 09/12/2001 | CN1312713A Pharmaceutical compositions containing lipase inhibitors |
| 09/12/2001 | CN1312372A Intocostrin regulation area and nucleotide series determination and method used thereof |
| 09/12/2001 | CN1312254A Novel nucleoside |
| 09/12/2001 | CN1312065A Use of compound for improving skin and its mucous membrane physical-chemical property to prevent adsorption of microorganism |
| 09/12/2001 | CN1070697C Method of preparing novel microcapsule |
| 09/11/2001 | US6288120 Prevention of loss and restoration of bone mass by certain prostaglandin agonists |
| 09/11/2001 | US6288118 Therapies for treating pulmonary diseases |
| 09/11/2001 | US6288113 Angiogenesis promoters |
| 09/11/2001 | US6288108 Methods for increasing levels of acetylcholine |
| 09/11/2001 | US6288090 Pharmaceutical composition |
| 09/11/2001 | US6288087 An extract from eupatorium purpurem, cytochrome p450 inducing compound, sugar, a source of phosphate, and one or more carriers |
| 09/11/2001 | US6288055 Analgesic agents |
| 09/11/2001 | US6288053 Use of protein kinase C inhibitors to enhance the clinical efficacy of radiation therapy |
| 09/11/2001 | US6288025 Protease inhibitors for use in the treatment of psoriasis |
| 09/11/2001 | US6287836 Histidine kinase from Streptococcus pneumoniae and compositions therecontaining |
| 09/11/2001 | US6287804 nrdG |
| 09/11/2001 | US6287803 Polynucleotides encoding a novel era polypeptide |
| 09/11/2001 | US6287786 Nucleic acid molecules encoding a new mammalian protein and to the use of these molecules in the characterization, diagnosis, and treatment of conditions such as disorders associated with cell proliferation, lipid metabolism and transport. |
| 09/11/2001 | US6287602 Treatment of oncologic tumors with an injectable formulation of a Golgi apparatus disturbing agent |
| 09/11/2001 | US6287601 Equine laminitis |
| 09/11/2001 | US6287599 Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| 09/11/2001 | US6287594 Oral liquid compositions |
| 09/11/2001 | US6287563 Administering heat labile entertoxin |
| 09/11/2001 | US6287540 Therapeutic dry powder |
| 09/11/2001 | CA2195119C Formulations and methods for providing prolonged local anesthesia |
| 09/07/2001 | WO2001064949A2 Diagnostics and therapeutics for glaucoma |
| 09/07/2001 | WO2001064944A1 MODULATION OF PLEIOTROPHIN SIGNALING BY RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE β/$g(z) |
| 09/07/2001 | WO2001064907A2 Lipid metabolism enzymes |
| 09/07/2001 | WO2001064896A2 Human enzyme molecules |
| 09/07/2001 | WO2001064885A1 Chordin-like-2 molecules and uses thereof |
| 09/07/2001 | WO2001064877A2 Human schizophrenia gene |
| 09/07/2001 | WO2001064876A2 Human schizophrenia gene |
| 09/07/2001 | WO2001064874A2 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 09/07/2001 | WO2001064837A2 β NETRIN AND USES THEREOF |
| 09/07/2001 | WO2001064755A2 Isoxazole gegen virale erkrankungen |
| 09/07/2001 | WO2001064741A2 Methods for selectively modulating survivin apoptosis pathways |
| 09/07/2001 | WO2001064707A1 Melanoma differentiation associated gene - 5 and promoter and uses thereof |
| 09/07/2001 | WO2001064692A1 Cardioprotective phosphonates and malonates |
| 09/07/2001 | WO2001064662A1 Allomorph isomer z hydrochloride of ranitidine |
| 09/07/2001 | WO2001064258A1 Agent for the treatment of wounds |
| 09/07/2001 | WO2001064255A1 Method for detecting and killing epithelial cancer cells |
| 09/07/2001 | WO2001064253A1 P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine |
| 09/07/2001 | WO2001064252A2 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| 09/07/2001 | WO2001064251A2 Combination chemotherapy |
| 09/07/2001 | WO2001064249A1 Tissue decomposition inhibitor |
| 09/07/2001 | WO2001064247A2 Method of treating cancer with anti-neurotrophin agents |
| 09/07/2001 | WO2001064246A2 Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| 09/07/2001 | WO2001064245A1 Immune enhancement compositions and use thereof |
| 09/07/2001 | WO2001064236A2 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS |
| 09/07/2001 | WO2001064235A1 Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d |
| 09/07/2001 | WO2001064225A1 Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response |
| 09/07/2001 | WO2001064223A1 Method for treating or preventing depression |
| 09/07/2001 | WO2001064218A2 Farnesyl protein transferase inhibitor combinations |
| 09/07/2001 | WO2001064217A2 Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| 09/07/2001 | WO2001064215A1 Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis |
| 09/07/2001 | WO2001064214A2 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| 09/07/2001 | WO2001064205A2 Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
| 09/07/2001 | WO2001064203A2 Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q¿10? |
| 09/07/2001 | WO2001064202A2 Tramadol for the treatment of functional gastrointestinal disorders |
| 09/07/2001 | WO2001064200A2 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| 09/07/2001 | WO2001064198A2 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| 09/07/2001 | WO2001064197A2 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 09/07/2001 | WO2001064196A2 Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| 09/07/2001 | WO2001064195A2 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| 09/07/2001 | WO2001064192A2 Use of benzothieno-2,3-d-pyrimidines with pde v inhibitory effect for the treatment of erectile dysfunction |
| 09/07/2001 | WO2001064185A2 Method for making, loading and sealing a cell or drug encapsulation device, and such a device |
| 09/07/2001 | WO2001064167A1 Cosmetic and pharmaceutical preparations for treating cellulite |
| 09/07/2001 | WO2001064110A1 Method for detecting and killing epithelial cancer cells |
| 09/07/2001 | WO2001064058A1 Strengthening natural healing drink |
| 09/07/2001 | WO2001064008A2 Vaccine for the treatment of artherosclerosis |
| 09/07/2001 | WO2001019780A3 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 09/07/2001 | WO2001010423A3 Use of 5-ht3 receptor antagonists for the treatment of inflammations of the respiratory tract |
| 09/07/2001 | WO2001000197A3 Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
| 09/07/2001 | WO2000071571A3 Fap-activated anti-tumor compounds |
| 09/07/2001 | WO2000062765A3 ESTROGEN RECEPTOR-β LIGANDS |
| 09/07/2001 | WO2000051584A3 Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists |
| 09/07/2001 | WO2000047618A3 HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES |
| 09/07/2001 | CA2401869A1 Agent for the treatment of wounds |
| 09/07/2001 | CA2401775A1 Diagnostics and therapeutics for glaucoma |
| 09/07/2001 | CA2401755A1 Vaccine for the treatment of artherosclerosis |
| 09/07/2001 | CA2401741A1 Melanoma differentiation associated gene - 5 and promoter and uses thereof |
| 09/07/2001 | CA2401670A1 Human enzyme molecules |
| 09/07/2001 | CA2401665A1 Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d |
| 09/07/2001 | CA2401660A1 Lipid metabolism enzymes |
| 09/07/2001 | CA2401633A1 Modulation of pleiotrophin signaling by receptor-type protein tyrosine phosphatase .beta./.zeta. |
| 09/07/2001 | CA2401607A1 Methods for selectively modulating survivin apoptosis pathways |
| 09/07/2001 | CA2401585A1 Use of pde v inhibitors |
| 09/07/2001 | CA2401405A1 Medicament for viral diseases |
| 09/07/2001 | CA2401357A1 Tissue degradation inhibitor agent |
| 09/07/2001 | CA2401352A1 Immune enhancement compositions and use thereof |
| 09/07/2001 | CA2401340A1 Compositions and methods for the treatment of inflammatory disease using topoisomerase inhibitors |
| 09/07/2001 | CA2401304A1 Combination chemotherapy |
| 09/07/2001 | CA2401175A1 Chordin-like-2 molecules and uses thereof |